1Scheer S,Morel C,Poisson F,et al.Prevention of proliferative vitreoretinopathy using 5-FU heparin:clinical tolerance and efficacy[J].J Fr Ophtalmol,2005,28(7):701-706.
2Kang SG,Chung H,Yoo YD,et al.Mechanism of growth inhibitory effect of Mitomycin-C on cultured human retinal pigment epithelial cells:apoptosis and cell cycle arrest[J].Curr Eye Res,2001,22(3):174-181.
6Wiedemann P,Hilgers RD,Bauer P,et al.Adjunctive daunorubicin in the treatment of proliferative vitreoretinopathy:results of a multicenter clinical trial.Daunomycin Study Group[J].Am J Ophthalmol,1998,126 (4):550-559.
7Couch SM,Bakri SJ.Use of triamcinolone during vitrectomy surgery to visualize membranes and vitreous[J].Clin Ophthalmol,2008,2(4):891-896.
8Acar N,Kapran Z,Altan T,et al.Pars plana vitrectomy with and without triamcinolone acetonide assistance in pseudophakic retinal detachment complicated with proliferative vitreoretinopathy[J].Jpn J Ophthalmol,2010,54(4):331-337.
9Larrosa JM,Veloso AA Jr,Leong FL,et al.Antiproliferative effect of intravitreal alpha-tocopherol and alpha-tocopheryl-acid-succinate in a rabbit model of PVR[J].Curr Eye Res,1997,16(10):1030-1035.
7Kirchhof B, Sorgente N. Pathogenesis of proliferative vitreoretinopathy. Dev Ophthalmol, 1989, 16: 1-53.
8Weller M, Wiedemann P. Heimann K. Proliferative vitreoretinopathy is it anything more than wound healing at the wrong place? Int Ophthalmol, 1990, 14: 105-117.
9Hui YN, Liang HC, Cai YS, et al. Corticosteroids and daunomvcin in the prevention of experimental proliferative vitreoretinopathy induced by macrophages. Graefes Arch Clin Exp Ophthalmol, 1993, 231: 109-114.
10Hui YN, Sorgente N, Ryan SJ. Posterior vitreous separation and retinal detachment induced by macrophages. Graefes Arch Clin Exp Ophthalmol, 1987, 225: 297-284.
1Sunalp M A, Wiedemann P, Sorgente N, et al. Effect of adriamycin on experimental proliferative Vitreoretinopa- thy in the rabbit[J]. EXP Eye Res,1985, 41:105.
2Moritera T, Ogura Y,Yoshimura N, et al. Biodegradable Mierospheres containing adriamyein in the treatment of proliferative Vitreoretinopathy [J]. Invest Ophthalmol Vis Sei,1992,33:3125.
3Fastenlberg D M, Diddie K R, Sorgente N,et al. A com- parisonof different cellular inocula in an experimental modelof massive periretinal proliferation[J]. Am J Oph- thalmol, 1982,93 : 559-572.
4Parapuram S K,Chang B,Li L, et al. Differential effects of TGF3 and vitreous on the transformation of retinal pig- ment epithelial cells [J]. Invest Ophthalmol Vis Sei, 2009,50(12) : 5965-5974.
5Peyman G A, Schulman J A. lntravitreal drug therapy [M]. Jpn J Ophthalmol, 1989,33:392.
